Novogen’s “Comprehensive Science Review”

What a complete and utter farce. At the end of July, acting CEO Iain Ross informed that markets that he would be conducing a systematic review of Novogen’s (ASX : NRT) prospects, with the goal of a shareholder update by the 1st of September. Today, we received the promised progress update in the form of…

A Tale of Two Companies

I honestly can’t recall the moment I felt compelled to bastardise Dickens. I suspect that it has been a gradual accumulation of neural triggers, little seismic bursts of thought association that gradually – over thousands of words – build into a tsunami of recognition that eventually crushes the civilisation of the mind. Thought association. Hmmmm. Was it the…

Keeping the flame alive…

Today, once again, Novogen announced that it has filed a couple of patents. Not received a notice of allowance or won an opposition or anything of commercial significance, but you know, just paperwork. Well done to Andrew Heaton and the team for getting some cunning new technology put down on the page – and especially a…

Novogen’s Graham Kelly : Jumped or Pushed?

Intriguing stuff – you no doubt know that today Dr. Graham Kelly, CEO of Novogen, resigned from the company. In a reasonably perfunctory statement, it has been announced that Dr. Kelly will “leave the Company to resume his work in non-oncology based early stage research.” Well, clearly, it would have to be non-oncology based research, because…

The Bioshares 2015 : “Long Tail” Awards

Unfortunately, I will not be at Bioshares in New Zealand this weekend to present these well-deserved awards on behalf of the dedicated readers of The Long Tail. However, I have ordered a crate of North Korean Kumdang-2 as the prize for these awards and as soon as it clears AQIS, I will be sure and distribute…

The Cancer Stem Cell Hypothesis

When I first read that HC Wainwright had initiated coverage on Novogen (ASX : NRT) today, I was pretty much prepared to go in guns blazing on yet another paid-for and underwhelming analyst report. I was even going to ask the basic question that every self-styled ASX biotech pundit should ask, and that is “what cereal…